Summary & Overview
CPT 50590: Extracorporeal Shock Wave Lithotripsy for Urinary Stones
CPT code 50590 covers extracorporeal shock wave lithotripsy, a widely used urological procedure for treating urinary tract stones. This code is significant nationally due to its role in providing a non-invasive alternative to surgical stone removal, improving patient outcomes and reducing recovery times. The procedure is most often performed in outpatient hospital settings and is relevant for patients diagnosed with kidney, ureter, or bladder stones.
Major payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare provide coverage for this service, reflecting its clinical importance and broad utilization. Readers will gain insight into payer coverage policies, typical clinical indications, and related billing practices. The publication also addresses common modifiers used for billing, associated physician taxonomies, and relevant ICD-10 diagnoses. Additionally, it highlights related CPT codes that may be billed in conjunction with lithotripsy, offering a comprehensive overview of the procedure's place in urological care and medical billing.
This summary provides a clear understanding of the clinical context, payer landscape, and coding considerations for CPT 50590, equipping stakeholders with essential information for policy review and operational planning.
CPT Code Overview
CPT 50590 represents lithotripsy, extracorporeal shock wave, a procedure commonly performed in the field of urology. This service is typically provided in an outpatient hospital setting, designated as Place of Service 22. Lithotripsy utilizes shock waves to break up stones in the urinary tract, offering a non-invasive treatment option for patients with kidney, ureter, or bladder stones.
Clinical & Coding Specifications
Clinical Context
A patient presents to the outpatient hospital with symptoms such as flank pain, hematuria, or urinary obstruction. Imaging studies confirm the presence of a urinary calculus, such as a kidney stone or ureteral stone. The urology physician determines that extracorporeal shock wave lithotripsy is appropriate for stone fragmentation. The procedure is performed in the outpatient setting, with the patient under sedation or anesthesia. The care team may include a urology physician, surgical oncology physician, or radiation oncology physician, depending on the complexity. Post-procedure, the patient is monitored for stone passage and potential complications.
Coding Specifications
-
Modifiers:
- Modifier
26: Used to indicate the professional component of the procedure, typically when the physician interprets the results or supervises the procedure. - Modifier
TC: Used for the technical component, representing the use of equipment and facility resources. - Modifier
59: Indicates a distinct procedural service, used when multiple procedures are performed and need to be reported separately.
- Modifier
-
Provider Taxonomies:
Taxonomy Code Specialty Name 208800000XUrology Physician 2086S0122XSurgical Oncology Physician 2085R0202XRadiation Oncology Physician
These taxonomies represent the specialties typically involved in performing or supervising extracorporeal shock wave lithotripsy.
Related Diagnoses
-
N20.0- Calculus of kidney- Indicates kidney stones, which are a primary indication for extracorporeal shock wave lithotripsy.
-
N20.1- Calculus of ureter- Refers to stones located in the ureter, also commonly treated with lithotripsy.
-
N20.2- Calculus of kidney with calculus of ureter- Represents patients with stones in both the kidney and ureter, suitable for lithotripsy.
-
N20.9- Urinary calculus, unspecified- Used when the exact location of the stone is not specified, but lithotripsy may still be indicated.
-
N21.0- Calculus in bladder- Refers to bladder stones, which may be managed with lithotripsy depending on size and location.
Related CPT Codes
-
52005- Cystourethroscopy, with ureteral catheterization- Used to visualize the urinary tract and may be performed before or after lithotripsy to assess stone location or facilitate stone removal.
-
52332- Cystourethroscopy, with insertion of indwelling ureteral stent- May be used in conjunction with lithotripsy to place a stent for urinary drainage or to prevent obstruction from stone fragments.
-
74420- Urography, retrograde, with or without KUB- Imaging procedure that can be used to evaluate the urinary tract before or after lithotripsy.
-
76856- Ultrasound, pelvic (nonobstetric), real time with image documentation- Utilized for imaging to locate stones or assess post-procedure outcomes.
These codes are commonly used together in the clinical workflow for stone management, either as preparatory, adjunct, or follow-up procedures.
National Reimbursement Benchmarks
For CPT code 50590, the national mean rate for Medicare is $782.20, while the BUCA (average commercial) mean rate is $943.30. Commercial payers such as UnitedHealth Group and Cigna have notably higher mean rates, with UnitedHealth Group at $1,228.22 and Cigna at $1,114.07, compared to Medicare.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Medicare shows the tightest range at $70.00, indicating relatively consistent rates nationally. In contrast, UnitedHealth Group exhibits the widest dispersion at $689.00, reflecting greater variability in contracted rates. Cigna and Blue Cross Blue Shield also display substantial ranges, at $597.00 and $406.68 respectively.
The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.